TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33550636

Group type: EXPERIMENTAL
Intervention: UBDRS seizure score
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ABC and CSF NEFL
Number of subjects: 20
Study: 33550824

Group type: EXPERIMENTAL
Intervention: Furosemide, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study: 33550846

Group type: EXPERIMENTAL
Intervention: Oral fluid testing (OFT) - supervised testing
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Oral fluid testing (OFT) - unsupervised testing
Number of subjects: 813

Group type: COMPARATOR
Intervention: Before intervention
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: During intervention
Number of subjects: 813
Study: 33550890

Group type: EXPERIMENTAL
Intervention: K-Nearest Neighbors (K-NNs) classification model
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Binomial logistic regression classification model
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) classification model
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Naïve Bayes classification model
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ensemble model
Number of subjects: 140
Study: 33551075

Group type: EXPERIMENTAL
Intervention: Controlling Nutritional Status score
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Prognostic Nutritional Index
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Controlling Nutritional Status score + European System for Cardiac Operative Risk Evaluation II
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Severity of malnutrition (as per Kaplan-Meier survival curve)
Number of subjects: 1927
Study: 33551218

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 59
Study: 33551398

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (historical IVL control)
Number of subjects: 64
Study: 33551777

Group type: EXPERIMENTAL
Intervention: BCI-guided robot hand training
Number of subjects: 14
Study: 33551948

Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation, details on dosage and duration not available
Number of subjects: 0
Study: 33551974

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA ≤400 U
Number of subjects: 0
Study: 33551992

Group type: EXPERIMENTAL
Intervention: Lutetium 177-DOTATATE therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Periodic evaluation of TFTs
Number of subjects: 1
Study: 33552568

Group type: EXPERIMENTAL
Intervention: Combined epidural/general anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (combined and general anesthesia)
Number of subjects: 50
Study: 33553232

Group type: EXPERIMENTAL
Intervention: Multimodal resistance training protocol with adequate protein intake and leucine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33553233

Group type: EXPERIMENTAL
Intervention: 6 g of cinnamon added to oatmeal prepared with milk
Number of subjects: 0
Study: 33553313

Group type: EXPERIMENTAL
Intervention: 1.9-mm cryoprobes
Number of subjects: 216

Group type: COMPARATOR
Intervention: 2.4-mm cryoprobes
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both probes
Number of subjects: 216
Study: 33553366

Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 0
Study: 33553651

Group type: EXPERIMENTAL
Intervention: Self-report of emergency department (ED) visits
Number of subjects: 169

Group type: COMPARATOR
Intervention: Emergency Department Information Exchange (EDIE)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Self-report of ED visits
Number of subjects: 169

Group type: COMPARATOR
Intervention: EDIE
Number of subjects: 169
Study: 33553800

Group type: EXPERIMENTAL
Intervention: RunIn3 program
Number of subjects: 530
Study: 33553968

Group type: EXPERIMENTAL
Intervention: REP 2139-Ca and Pegylated Interferon (pegIFN)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: REP 2139-Ca monotherapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Follow-up after therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Safety and tolerability
Number of subjects: 11
Study: 33554038

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg intravenously every 3 weeks)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: HLA-C heterozygosity
Number of subjects: 101
Study: 33554315

Group type: EXPERIMENTAL
Intervention: Unified Multiple System Atrophy Rating Scale (UMSARS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert consensus assessment
Number of subjects: 0
Study: 33554514

Group type: EXPERIMENTAL
Intervention: Mid-regional pro-adrenomedullin (MR-proADM)
Number of subjects: 657

Group type: COMPARATOR
Intervention: SOFA score alone
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: SOFA score + MR-proADM
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: MR-proADM threshold of 1.75 nmol/L
Number of subjects: 657
Study: 33554732

Group type: EXPERIMENTAL
Intervention: CD44v6-NWN2.CAR T cells with LNGFR spacer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different LNGFR spacers
Number of subjects: 0
Study: 33555033

Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg single oral dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg daily, 3 weeks on and 1 week off
Number of subjects: 30
Study: 33555258

Group type: EXPERIMENTAL
Intervention: TeamSTEPPS intervention
Number of subjects: 80
Study: 33555265

Group type: EXPERIMENTAL
Intervention: START (Suicide-specific cognitive behavioral intervention)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: START with mobile augmentation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 70
Study: 33555272

Group type: EXPERIMENTAL
Intervention: RUNX2 targeting in immature and KMT2A-R T-ALL cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RUNX2 upregulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RUNX2 targeting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RUNX2 regulation of CXCR4 signaling
Number of subjects: 0
Study: 33555436

Group type: EXPERIMENTAL
Intervention: In-hospital treatment for COVID-19 in patients < 65 years
Number of subjects: 2676

Group type: EXPERIMENTAL
Intervention: Access to ICU and treatment with IMV in patients < 65 years
Number of subjects: 2676

Group type: EXPERIMENTAL
Intervention: Predictors of case fatality in young patients
Number of subjects: 2676

Group type: COMPARATOR
Intervention: Comparison with elderly patients (≥ 65 years)
Number of subjects: 2676
Study: 33555456

Group type: EXPERIMENTAL
Intervention: Warm vertical compaction technique (WVT) with gutta percha and epoxy resin-based sealer (AH Plus Jet)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sealer-based filling technique (SBT) with single cone gutta percha and calcium silicate-based sealer (EndoSequence BC Sealer)
Number of subjects: 92
Study: 33555777

Group type: COMPARATOR
Intervention: No organ support (n = 15,001)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (n = 5,005; 24.3%)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation only (n = 1,749)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation, vasoactive drugs, and new renal replacement therapy (n = 655)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (n = 389)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Discharge home (no organ support)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Discharge home (invasive mechanical ventilation only)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Discharge home (invasive mechanical ventilation, vasoactive drugs, and renal replacement)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Discharge home (invasive mechanical ventilation, age > 74 years)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Hospital length of stay (mechanical ventilation)
Number of subjects: 20608

Group type: EXPERIMENTAL
Intervention: Adjusted interhospital variation in mortality (invasive mechanical ventilation)
Number of subjects: 20608
Study: 33555780

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venous thromboprophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (compared with other corticosteroids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Convalescent plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic anticoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remdesivir in nonventilated patients with severe COVID-19
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remdesivir in patients with critical COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 0
Study: 33556206

Group type: EXPERIMENTAL
Intervention: nucleic acid polymers and pegIFN
Number of subjects: 40
Study: 33556347

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Number of subjects: 29
Study: 33556493

Group type: EXPERIMENTAL
Intervention: Palliative care intervention (PC) including a single in-person outpatient palliative care consultation (OPCC) plus 6 weekly, PC nurse coach-led telehealth sessions.
Number of subjects: 208

Group type: COMPARATOR
Intervention: Non-completers (those who did not attend the OPCC or completed <6 telehealth sessions).
Number of subjects: 208
Study: 33556845

Group type: EXPERIMENTAL
Intervention: MAMAACT intervention (training session and two dialogue meetings for midwives, leaflet and mobile application for women)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MAMAACT leaflet and app
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Midwives' reflections on practice due to training sessions and dialogue meetings
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Midwives' communication strategies
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Institutional structures and power relationships
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Midwives' task loads and time resources
Number of subjects: 48
Study: 33557591

Group type: EXPERIMENTAL
Intervention: hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
Number of subjects: 0
Study: 33557637

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly
Number of subjects: 2677
Study: 33557756

Group type: EXPERIMENTAL
Intervention: Plasma metabolomics-based biomarkers (ceramides, acyl-carnitines, fatty acids, galectin-3, adiponectin, apolipoprotein B/apolipoprotein A1 ratio)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Risk prediction algorithm combining clinical characteristics with established and novel biomarkers
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Follow-up after 12 months
Number of subjects: 1065
Study: 33557831

Group type: EXPERIMENTAL
Intervention: Symptom-based screening
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tuberculin skin-based screening
Number of subjects: 16
Study: 33557834

Group type: EXPERIMENTAL
Intervention: Andago (bodyweight unloading at 20%, 35%, and 50%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Andago
Number of subjects: 18
Study: 33557844

Group type: EXPERIMENTAL
Intervention: 5-fluorouracile-based treatments (first- and second-line)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Treatment withdrawal and cancer progression
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 1
Study: 33558093

Group type: EXPERIMENTAL
Intervention: Ideal body mass index (BMI)
Number of subjects: 2047

Group type: EXPERIMENTAL
Intervention: Ideal physical activity
Number of subjects: 2047

Group type: EXPERIMENTAL
Intervention: Non-smoking
Number of subjects: 2047

Group type: EXPERIMENTAL
Intervention: Ideal diet
Number of subjects: 2047

Group type: COMPARATOR
Intervention: Smoking prevalence in females
Number of subjects: 2047

Group type: COMPARATOR
Intervention: Physical activity in females
Number of subjects: 2047

Group type: COMPARATOR
Intervention: Dietary habits in females
Number of subjects: 2047

Group type: COMPARATOR
Intervention: Age-related smoking and diet prevalence
Number of subjects: 2047

Group type: COMPARATOR
Intervention: BMI and diet in apprentices vs. academic students
Number of subjects: 2047

Group type: COMPARATOR
Intervention: Smoking prevalence in apprentices
Number of subjects: 2047

Group type: COMPARATOR
Intervention: Association of non-ideal BMI with smoking
Number of subjects: 2047
Study: 33558125

Group type: EXPERIMENTAL
Intervention: Low-dose cone-beam CT angiography (5-second rotation, n=45)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard cone-beam CT angiography (6-second rotation, n=29)
Number of subjects: 21
Study: 33558152

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus acetylsalicylic acid (ASA)
Number of subjects: 154369

Group type: COMPARATOR
Intervention: Placebo plus acetylsalicylic acid (ASA)
Number of subjects: 154369

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 154369
Study: 33558163

Group type: EXPERIMENTAL
Intervention: Acknowledgement of healthcare professional (HCP) responsibility to contribute to weight loss
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: Comfort in talking to their HCP about weight
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: Agreement that it is easy to lose weight
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: Goal of reducing risks from excess weight
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: Consideration of obesity less important than other diseases
Number of subjects: 10854

Group type: EXPERIMENTAL
Intervention: Exercise ≥5 times a week
Number of subjects: 10854
Study: 33558202

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing-based MRD assay
Number of subjects: 16
Study: 33558239

Group type: EXPERIMENTAL
Intervention: Genomic risk scores for schizophrenia (GRSs) in the presence of early-life complications (ELCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genomic risk scores for schizophrenia (GRSs) in the absence of early-life complications (ELCs)
Number of subjects: 0
Study: 33558267

Group type: EXPERIMENTAL
Intervention: Metabolically Healthy Obese (MHO)
Number of subjects: 4381

Group type: EXPERIMENTAL
Intervention: Metabolically Unhealthy (MUN and MUO)
Number of subjects: 4381
Study: 33558294

Group type: EXPERIMENTAL
Intervention: Micafungin 8 mg/kg daily for a mean of 13.3 days (±5.2 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Micafungin 8 mg/kg daily
Number of subjects: 35
Study: 33558353

Group type: EXPERIMENTAL
Intervention: Individual communication strategies (rational explanation, seduction, empathy)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Confrontation or flight strategies
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Collective intervention for managing deviant behaviours
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mediators specialized in conflict resolution
Number of subjects: 38
Study: 33558356

Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation programme
Number of subjects: 355
Study: 33558436

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg plus standard therapy
Number of subjects: 836

Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 836
Study: 33558725

Group type: EXPERIMENTAL
Intervention: T cells engineered with a T cell receptor targeting HPV-16 E7
Number of subjects: 0
Study: 33559089

Group type: EXPERIMENTAL
Intervention: Hepatic Steatosis Index (HSI)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Nonalcoholic Fatty Liver Disease Liver Fat Score (NAFLD-LFS)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Triglyceride Glucose (TyG) index
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Index (VAI)
Number of subjects: 394
Study: 33559286

Group type: EXPERIMENTAL
Intervention: Rituximab treatment in DLBCL patients who are HBsAg positive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab treatment in DLBCL patients who are HBsAg negative
Number of subjects: 0
Study: 33559346

Group type: EXPERIMENTAL
Intervention: Chronic heart failure with preserved ejection fraction (HFpEF)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chronic heart failure with reduced ejection fraction (HFrEF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 81
Study: 33559765

Group type: EXPERIMENTAL
Intervention: NIV alternating with high-flow nasal oxygen
Number of subjects: 150

Group type: COMPARATOR
Intervention: High-flow nasal oxygen alone
Number of subjects: 150
Study: 33559777

Group type: EXPERIMENTAL
Intervention: Ultrasonographic B-lines score at a cut-off of 15
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: B-profile pattern
Number of subjects: 700
Study: 33559842

Group type: EXPERIMENTAL
Intervention: Twice-weekly 25-mg prefilled liquid Yisaipu (group I)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Once-weekly 50-mg prefilled liquid Yisaipu (group II)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Twice-weekly 25-mg lyophilized Yisaipu (group III)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 640
Study: 33560090

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study: 33560097

Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg loading dose followed by 100 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Micafungin 100 mg daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: CVVH
Number of subjects: 16

Group type: COMPARATOR
Intervention: CVVHDF
Number of subjects: 16
Study: 33560234

Group type: EXPERIMENTAL
Intervention: IDEAL CGM web-based training intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enhanced standard care plus IDEAL CGM intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 8
Study: 33560240

Group type: EXPERIMENTAL
Intervention: Integrated Engagement Support System
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 33560372

Group type: EXPERIMENTAL
Intervention: Low caloric diet (LCD; 800 kcal/d) in DiOGenes study
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Weight maintenance following LCD in DiOGenes study
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Low caloric diet (LCD; 800-1000 kcal/d) in Finnish CRYO study
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery in KOBS study
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery in DEOSH study (2-year follow-up)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery in DEOSH study (5-year follow-up)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery (proteomics level)
Number of subjects: 261
Study: 33560375

Group type: EXPERIMENTAL
Intervention: Multiagent initial chemotherapy
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Multiagent initial chemotherapy with anthracycline and etoposide
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation
Number of subjects: 235
Study: 33560384

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Denosumab (ASCT-intent subgroup, frontline triplet)
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Denosumab (ASCT-intent subgroup, bortezomib-only)
Number of subjects: 1718
Study: 33560394

Group type: EXPERIMENTAL
Intervention: IV copanlisib 60 mg on days 1, 8, and 15 of 28-day cycles for a median of 23 weeks
Number of subjects: 23
Study: 33560399

Group type: EXPERIMENTAL
Intervention: Omidubicel in combination with unmanipulated UCB graft
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single omidubicel graft
Number of subjects: 16
Study: 33560404

Group type: EXPERIMENTAL
Intervention: Cardiogenic Shock (CS) patients
Number of subjects: 4856

Group type: EXPERIMENTAL
Intervention: Risk factors for developing CS
Number of subjects: 4856

Group type: EXPERIMENTAL
Intervention: Risk factors for mortality
Number of subjects: 4856
Study: 33560478

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advanced testing using next-generation sequencing
Number of subjects: 0
Study: 33560583

Group type: EXPERIMENTAL
Intervention: Foot orthoses for 6 months
Number of subjects: 6
Study: 33560746

Group type: EXPERIMENTAL
Intervention: Intervention not specified; details not available.
Number of subjects: 0
Study: 33560866

Group type: EXPERIMENTAL
Intervention: Isokinetic strength testing and 3-dimensional biomechanical analysis of jump and change-of-direction tests 9 months after ACLR
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Quadriceps strength and plyometric ability targeting during late-stage rehabilitation
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Patient-reported outcomes, limb symmetry of clinical performance measures, and biomechanical measures in change-of-direction tasks
Number of subjects: 1045
Study: 33560905

Group type: EXPERIMENTAL
Intervention: Rapid-EEG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical suspicion alone
Number of subjects: 0
Study: 33561010

Group type: EXPERIMENTAL
Intervention: CRISPR-augmented RT-PCR assay
Number of subjects: 159

Group type: COMPARATOR
Intervention: RT-qPCR nasal/nasopharyngeal test
Number of subjects: 159
Study: 33561011

Group type: EXPERIMENTAL
Intervention: Insulin deprivation for 5.4 ± 0.6 hours in T1D participants
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Insulin deprivation in T1D participants
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline comparison with ND participants
Number of subjects: 28